COMPARATIVE EFFICACY AND TOLERABILITY OF CLARITHROMYCIN AND AMOXYCILLIN IN THE TREATMENT OF OUT-PATIENTS WITH ACUTE MAXILLARY SINUSITIS

被引:29
作者
MARCHI, E
机构
[1] Faculty of Medicine, University of Milan, Milan
关键词
Acute Maxillary; Amoxicillin; Clarithromycin; Sinusitis;
D O I
10.1185/03007999009111487
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The efficacy and tolerability of clarithromycin and amoxycillin in the treatment of acute maxillary sinusitis were compared in an open, Phase III multi-centre study. Sixty-one out-patients (40 males, 21 females) received clarithromycin (two 250 mg tablets twice daily) and 59 (34 males, 25 females) out-patients received amoxycillin (two 500 mg capsules twice daily). Fifty-seven and 47patients in the clarithromycin group were evaluable for clinical efficacy and bacteriological effectiveness, respectively. In the amoxycillin group, 57 and 40 patients were evaluated for clinical efficacy and bacteriological effectiveness, respectively. Body temperature, bacteriological culture results, blood and urine chemistries, and clinical signs and symptoms were evaluated prior to drug administration, between Days 4 to 6 and between Days 9 to 11 of treatment, and within 48 hours and, if required, 6 weeks after the end of treatment. Clinical signs and symptoms improved significantly (p<0.001) in both treatment groups. When evaluated within 48 hours after the end of treatment, there was no significant difference between the clinical success rate for clarithromycin (91%) and amoxycillin (84%) nor in the number of patients whose original pathogen was eradicated (89% clarithromycin, 93% amoxycillin). Six patients reported adverse events, 2 with clarithromycin (urticaria, gastro-intestinal) and 4 with amoxycillin (2 urticaria, 2 gastro-intestinal). Clarithromycin was comparable to amoxycillin with respect to clinical efficacy and tolerability and offers a useful addition to the available therapies for the treatment of acute maxillary sinusitis. © 1990 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted.
引用
收藏
页码:19 / 24
页数:6
相关论文
共 10 条
[1]   AN INVITRO EVALUATION OF THE CELLULAR UPTAKE AND INTRAPHAGOCYTIC BIOACTIVITY OF CLARITHROMYCIN (A-56268, TE-031), A NEW MACROLIDE ANTIMICROBIAL AGENT [J].
ANDERSON, R ;
JOONE, G ;
VANRENSBURG, CEJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 (06) :923-933
[2]  
BACHAND R, 1989, FEB PROGR ABSTR PAN
[3]   INVITRO ACTIVITY OF A-56268 (TE-031), A NEW MACROLIDE, COMPARED WITH THAT OF ERYTHROMYCIN AND CLINDAMYCIN AGAINST SELECTED GRAM-POSITIVE AND GRAM-NEGATIVE ORGANISMS [J].
BENSON, CA ;
SEGRETI, J ;
BEAUDETTE, FE ;
HINES, DW ;
GOODMAN, LJ ;
KAPLAN, RL ;
TRENHOLME, GM .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (02) :328-330
[4]  
Fernandes P. B., 1987, Antimicrobic Newsletter, V4, P25, DOI 10.1016/0738-1751(87)90002-5
[5]  
FERNANDES PB, 1988, DRUG EXP CLIN RES, V14, P441
[6]  
FERNANDES PB, 1986, 26TH PROGR ABSTR INT
[7]   CHEMICAL MODIFICATION OF ERYTHROMYCINS .1. SYNTHESIS AND ANTIBACTERIAL ACTIVITY OF 6-O-METHYLERYTHROMYCINS-A [J].
MORIMOTO, S ;
TAKAHASHI, Y ;
WATANABE, Y ;
OMURA, S .
JOURNAL OF ANTIBIOTICS, 1984, 37 (02) :187-189
[8]  
OTTERSON MF, 1990, IN PRESS FED AM SOC, V3
[9]  
SENNELLO LT, 1986, 26TH PROGR ABSTR INT
[10]  
1988, UNPUB